Revumenib

Revumenib
Clinical data
Other names	SNDX-5613
Identifiers
	IUPAC name N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide;
CAS Number	2169919-21-3;
PubChem CID	132212657;
ChemSpider	95502909;
UNII	LZ0M43NNF2;
KEGG	D12728;
ChEMBL	ChEMBL4650827;
Chemical and physical data
Formula	C32H47FN6O4S
Molar mass	630.82 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC;
	InChI InChI=InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3; Key:FRVSRBKUQZKTOW-UHFFFAOYSA-N;

Revumenib is an investigational new drug being evaluated for the treatment of acute leukemias harboring KMT2A rearrangements or mutant NPM1. It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), which plays a crucial role in the pathogenesis of these leukemias.^[1]

As of 2024, revumenib is under priority review by the U.S. Food and Drug Administration (FDA) for use in adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia, based on results from the phase 2 AUGMENT-101 clinical trial.^[2]

References

^ Hussain H, Zaidi SM, Hasan SM, Jahan AS, Rangwala BS, Rangwala HS, et al. (May 2024). "Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML)". Annals of Medicine and Surgery (2012). 86 (5): 2379–2381. doi:10.1097/MS9.0000000000001888. PMC 11060303. PMID 38694289.
^ "Revumenib Receives FDA Priority Review in R/R KMT2Ar Acute Leukemia". Cancer Network. 27 March 2024.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Hussain_2024-1] Hussain H, Zaidi SM, Hasan SM, Jahan AS, Rangwala BS, Rangwala HS, et al. (May 2024). "Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML)". Annals of Medicine and Surgery (2012). 86 (5): 2379–2381. doi:10.1097/MS9.0000000000001888. PMC 11060303. PMID 38694289.

[2] "Revumenib Receives FDA Priority Review in R/R KMT2Ar Acute Leukemia". Cancer Network. 27 March 2024.

[1]

[2]